Boom in weight-loss drugs to drive up US employers' medical costs in
2024 - Mercer
Send a link to a friend
[November 18, 2023]
By Leroy Leo and Khushi Mandowara
(Reuters) - Booming demand for newer weight-loss and diabetes drugs is
expected to accelerate the rise in medical expenses for employers in the
United States next year, staff health benefits consultant Mercer said on
Friday.
GLP-1 medications approved by the U.S. Food and Drug Administration
could contribute between 50 and 100 basis points to the trend, Mercer's
Chief Health Actuary, Sunit Patel, told Reuters in an interview.
U.S. employers, on average, have budgeted a likely 5.2% rise in these
costs for next year, according to Mercer's survey of nearly 1,900
employers, representing about 134,000 employer health plan sponsors.
An upswing in the use of GLP-1 drugs has had a notable impact on the
higher growth of pharmacy benefit costs under such health insurance
plans, Mercer said. In 2023, pharmacy benefit costs increased 8.4%
year-on-year, compared to 6.4% in 2022.
![](http://archives.lincolndailynews.com/2023/Nov/18/images/ads/current/farmersgrain_sda_FFARM_2023.png)
The higher cost associated with these drugs is due to their pricing as
well as the increasing number of patients, Mercer said. GLP-1 drugs,
which work by suppressing hunger and making a person feel full longer,
are typically priced around $1,000 per patient per month.
Earlier this month, U.S. and UK regulators approved Eli Lilly's
weight-loss treatment Zepbound, paving the way for a powerful new rival
to Novo Nordisk's Wegovy in a market estimated to generate $100 billion
in annual sales by the end of the decade.
While employers cover the use of GLP-1 drugs as a treatment for
diabetes, the debate around providing coverage for them as an obesity
treatment lingers. Currently, around two-fifths of large employers cover
GLP-1 medication for the treatment of obesity and another 19% say they
are considering it, Mercer said.
[to top of second column]
|
![](../images/111823PIX/health20.jpg)
A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is
shown in this photo illustration in Oslo, Norway, August31, 2023.
REUTERS/Victoria Klesty/Illustration/File Photo
![](http://archives.lincolndailynews.com/2023/Nov/18/images/ads/current/peasley_lda_051513.png) The impact of staff wage increases
by various hospitals on insurance plans is just phasing in, Patel
said.
"It may take another couple of years for price increases stemming
from higher healthcare sector wages and medical supply costs to be
felt across all health plans."
Despite rising health-plan costs, large employers have avoided
shifting additional costs to employees through higher deductibles,
co-pays, or out-of-pocket maximums in 2023.
Average insurance premium deductible for employees rose by just $2
at large companies this year and their share in the overall
healthcare cost was only 22% on average, similar to 2022, Mercer
said.
Most companies are expected to keep their staffers' share in
employer benefit costs at similar levels in 2024, said Beth Umland,
director of research for health and benefits at Mercer.
She said employers could instead offset the cost by offering
multiple plans and encouraging participation in options that offer
better discounts relative to the more expensive ones.
"Healthcare growth rising faster than the general inflation is a
concern. And we're going to be seeing this for a few years to come."
(Reporting by Khushi Mandowara and Leroy Leo in Bengaluru; Editing
by Pooja Desai)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
![](http://archives.lincolndailynews.com/2023/Nov/18/images/ads/current/charrons_bch_2022.png) |